Sequential therapy with ranibizumab and dexamethasone intravitreal implant is better than dexamethasone monotherapy for macular oedema due to retinal vein occlusion. Issue 2 (19th August 2014)

• Record Type: Journal Article
• Authors: Iu, Lawrence P; Zhao, Paul; Yeung, Ian Y; Fung, Nicholas S; Lee, Jacky W; Wong, Raymond L; Chong, Victor; Wong, Ian Y
• Is Part Of: British journal of ophthalmology. Volume 99:Issue 2(2015)
• Page Start: 210
• Page End: 214
• Publication Date: 2014-08-19
• Subjects: Retina; Ophthalmology -- Periodicals; 617.7
• DOI: 10.1136/bjophthalmol-2014-305661
• Languages: English
• ISSNs: 0007-1161

Abstract

Abstract : Purpose: To evaluate the efficacy and safety of sequential therapy with ranibizumab followed by dexamethasone intravitreal implant compared with dexamethasone monotherapy for macular oedema (MO) secondary to retinal vein occlusion (RVO). Methods: In this retrospective interventional study, the medical records of subjects with MO due to RVO who received either ranibizumab followed by dexamethasone intravitreal implant (Group 1) or dexamethasone-implant monotherapy (Group 2) were included. Primary outcome was the proportion of subjects who exhibited best-corrected visual acuity (VA) gain and resolution of MO within 6 months. Results: Thirty-three eyes were included (17 in Group 1, 16 in Group 2). More subjects in Group 1 exhibited a VA gain of at least 0.5 (LogMAR units hereafter) than Group 2 (29% vs 0%, p=0.044). The speed of VA gain was greater in Group 1 (1.4±0.8 months vs 2.7±1.4 months, p=0.020). MO was controlled in more subjects in Group 1 at all measured time intervals, and this difference was statistically significant at 3 months and 4 months. Subjects with branch RVO experienced VA gain more rapidly if they were from Group 1 (p=0.023). Conclusions: Sequential therapy was found to be more effective than dexamethasone monotherapy in treating MO due to RVO.